CTXB Protein - ACROBiosystems

Home
Products

products by category

Recombinant proteins
GMP Grade CytokinesNew Fc receptor proteins FcRn Proteins IgG Fc Proteins (Isotype Control) CGT development solutions New Targets of CAR-T cell therapy New Generation Tools for CAR DetectionStar Staining FDA DMF filed proteins Multi-pass TpsHot Immune checkpoint proteins ADC targets BsAb targets TME pathway targets CytokinesHot Enzymes Llama IgG Fc fusion protein Biosimilar drug targets Biomarkers & CD antigens All recombinant proteins

Antibodies
Anti-idiotypic antibody Anti-FMC63 mAb Neutralizing antibodies IgG Isotype Controls: Anti-DNP Antibodies
Support on research about infectious diseases Hot
Core reagents for infectious disease researchNew SARS-CoV-2 related products Reagents for vaccine development SARS-CoV-2 mutant products SARS-CoV-2 related kits Reagents for diagnostic development
Kits/Beads
Pre-coupling magnetic beads Inhinitor screening kits ELISA Assay Kits for Quantitative analysis of therapeutic antibodies in serum

Featured products

Pre-labeled proteins
New Generation Tools for CAR DetectionStar Staining Biotinylated protein collection FITC & PE labeled proteins
Full-length multi-pass TpsHot
Multi-pass Tps Claudin 18.2 GPCRs CD20 proteins
Proteins for Neuroscience
Proteins for Neuroscience New Pre-formed Fibrils (PFFs) New
Cytokines
ActiveMax Cytokines Hot Promising Therapeutic Targets Hot
Streptavidin (SA) series Products
SA, SA Coated Plates, SA Magnetic Beads New
Isotype Controls
Anti-DNP AntibodiesHot IgG Fc ProteinsHot Serum AlbuminHot

Hot targets
CD19 BCMA CD3 proteins IL-2 and IL-2 receptor proteins IL-6 and IL-6 receptor proteins Claudin 18.2 GPCRs CD20 proteins CD39/CD73 proteins B7 families TNFSF proteins VEGF proteins PD1 proteins TIGIT Siglec-15 proteins Integrin CD24&siglec-10

Brands
FLAG Star Staining ViruStop Aneuro ComboX ActiveMax GENPower
Services

Innovation Lab
SPR /BLI analytical serviceNew Enzyme-Linked Immunosorbent Assay (ELISA) Service New Meso Scale Discovery (MSD) ServiceNew Anti-Idiotypic Antibody Development ServiceNew Pseudovirus Neutralization Assay ServiceNew MHC Class I Complex Custom ServiceNew

Licensing Opportunities
Target 4-1BB monoclonal antibody New PD-1/CD80 bispecific antibodyNew Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1New Anti-PD-L1 / TIGIT bispecific antibodyNew TIGIT-Fc proteinNew Novel small molecule drug for cancer cachexiaNew
Supports

How to Order Shipping & Payments Global Distributors Testimonials FAQs Download COA
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression Claudin18.2-VLP：designed for CAR detection SPR & BLI：Binding activity assay SEC-MALS: Aggregation state and purity
News

News Insights Promotions Exhibitions
Resources

Download Brochures Download E-resources Download COA
ACROBiosystems

About Us Join Us Contact Us

CTXB

Brief Information

Name:Toxin B
Target Synonym:EC:3.4.22.-,Toxin B,toxB

Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved


CTB-V52E8	Vibrio cholerae serotype O1	Vibrio cholerae serotype O1 CTXB Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

CTB-V52E8

Vibrio cholerae serotype O1

Vibrio cholerae serotype O1 CTXB Protein, His Tag

Synonym Name

CTXB,TOXB

Background

Cholera enterotoxin subunit B (CTXB) is also known as cholera enterotoxin B chain, cholera enterotoxin gamma chain and choleragenoid. Vibrio cholerae O1 exists as two major serotypes, Inaba and Ogawa, which are associated with the O antigen of the lipopolysaccharide and are capable of unequal reciprocal interconversion. The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. CTXB can bind five GM1 gangliosides. Also, it has no toxic activity by itself.

Clinical and Translational Updates

Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Bezlotoxumab	CDB-1; MK-6072; MBL-CDB1; MDX-1388	Approved	Merck Sharp & Dohme Corp	Zinplava	Japan	Clostridium Infections; Diarrhea	Merck Sharp & Dohme Corp	2016-10-21	Clostridium Infections; Diarrhea	Details

Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
LMN-201	LMN-201			Clostridium Infections	Details
IMM-529	IMM-529		Immuron		Details
Ribaxamase	SYN-004(Synthetic Biologics)	Phase 2 Clinical	Synthetic Biologics	Graft vs Host Disease	Details